IntrinsicIntrinsic
OverviewFinancialsChartBusiness SummaryFilingsOwnershipValuation

Organon & Co. (OGN)

Business Summary

Organon & Co. is a global healthcare company focused on delivering impactful medicines and solutions, particularly in women's health. The company operates in the pharmaceutical and medical device industries, offering a portfolio of over 70 products across women's health and general medicines, including biosimilars . Organon generates revenue by selling these products through various channels such as drug wholesalers, retailers, hospitals, government agencies, and managed healthcare providers . Approximately 74% of Organon's 2025 revenues, or $4.6 billion , were generated outside the United States, indicating a significant global operational footprint.

The core business model revolves around a diverse product portfolio, with revenue generated from both established brands and newer biosimilars and women's health products. The company's strategy involves addressing health needs that uniquely, disproportionately, or differently affect women, while also expanding access to essential treatments in over 140 countries and territories . Organon also pursues collaborations with biopharmaceutical innovators to commercialize products by leveraging its scale and presence .

The Women's Health portfolio accounted for $1,752 million , or approximately 28% of total revenues in 2025. Key brands in this segment include Nexplanon® (etonogestrel implant), NuvaRing® (etonogestrel / ethinyl estradiol vaginal ring) for contraception, and Follistim AQ® (follitropin beta injection) for fertility . Nexplanon is noted as a long-acting reversible contraceptive with a low long-term average cost . The Jada® System, intended for postpartum uterine bleeding, was divested in January 2026 .

The General Medicines portfolio comprises Biosimilars and Established Brands. Biosimilars contributed $691 million , or approximately 11% of total revenues in 2025. This portfolio includes immunology biosimilars like Hadlima® (adalimumab-bwwd), Brenzys™ (etanercept), Renflexis® (infliximab-abda), and Tofidence® (tocilizumab-bavi), and oncology biosimilars such as Ontruzant® (trastuzumab-dttb), Aybintio™ (bevacizumab), Bildyos® (denosumab-nxxp), and Bilprevda® (denosumab-nxxp) . The Established Brands portfolio generated $3,691 million , or approximately 59% of total revenues in 2025, with approximately 91% , or $3.4 billion , generated outside the United States. This segment includes cardiovascular products like Zetia® (ezetimibe) and Cozaar® (losartan), respiratory products such as Singulair® (montelukast sodium) and Nasonex® (mometasone), and dermatology, bone health, and non-opioid pain management products including Vtama® (tapinarof) cream 1% and Fosamax® (alendronate sodium) .

For the fiscal year ended December 31, 2025, Organon reported total revenues of $6,216 million , a decrease of 3% compared to 2024 . Gross profit was $3,313 million , with a gross margin of approximately 53.3% (calculated as $3,313 million / $6,216 million). Operating income, calculated as Gross profit minus Selling, general and administrative, Research and development, Acquired in-process research and development and milestones, Goodwill impairment, and Restructuring costs, was $425 million . Net income for the period was $187 million . Diluted EPS was $0.72 . Cash and cash equivalents stood at $574 million , and total long-term debt was $8,628 million .

Year-over-year, worldwide sales decreased by 3% in 2025 compared to 2024. This decline was primarily due to lower sales of Atozet, Singulair, and Dulera, partially offset by increases in Vtama, Hadlima, Emgality, and Follistim . Cost of sales increased by 8% , while gross profit decreased by 11% . Selling, general and administrative expenses decreased by 2% , and Research and development expenses decreased by 22% . A significant operational development was the recognition of a $301 million goodwill impairment charge in 2025 .

During 2025, Organon discontinued the clinical development programs for investigational candidates OG-6219 and OG-7191 . In March 2025, Organon acquired the regulatory and commercial rights in the United States for Tofidence from Biogen Inc. for an upfront payment of $51 million . In November 2025, the FDA approved the Biologics License Application for Poherdy (pertuzumab-dpzb), a biosimilar to Perjeta . The company also launched Bildyos and Bilprevda biosimilars in the United States in 2025 . In July 2025, Organon acquired the Oss Biotech manufacturing facility in the Netherlands from Merck & Co., Inc. for aggregate consideration of $25 million . In January 2026, subsequent to the fiscal year-end, Organon divested the Jada System to Laborie Medical Technologies Corporation for up to $465 million .

Business Outlook & Financial Sufficiency

Organon's management has outlined a strategic shift in capital allocation, prioritizing deleveraging the business over acquiring new assets to expand its product portfolio . This is evidenced by actions taken in 2025, including a 90% reduction in the regular quarterly dividend payout ratio and the pursuit of product divestiture transactions, such as the sale of the Jada System in January 2026 for an aggregate payment of up to $465 million , with the goal of accelerating an improvement in net leverage. The company also aims to decrease its cost structure through restructuring initiatives aimed at driving operational efficiencies and cost savings .

One major growth area for Organon is the expansion of its women's health portfolio. The FDA approved a supplemental New Drug Application for Nexplanon in January 2026, extending its duration of use from three years to five years . Organon submitted a similar application for a five-year duration period of use to the EU and UK Health Authorities in 2025, with an expected outcome in 2026 . The company also expects to submit applications for marketing exclusivity in certain parts of the world, including Latin America, in 2026 . This extended indication for Nexplanon could potentially lead to an additional three years of clinical investigation exclusivity in the United States .

Another growth vector is the biosimilars portfolio. In 2025, Organon launched Bildyos injection 60 mg/mL and Bilprevda injection 120 mg/1.7 mL, biosimilars to Prolia and Xgeva, respectively, in the United States . Poherdy (pertuzumab-dpzb) was approved by the U.S. Food and Drug Administration in November 2025 , and the company is assessing its future commercial launch, with an intention to launch in the United States in late 2028 in accordance with a settlement and license agreement . The company also acquired U.S. commercialization rights for Tofidence in March 2025 , a biosimilar to Actemra, which launched in the U.S. market in May 2024 .

Operationally, Organon anticipates continuing to incur costs associated with the separation of its supply chain from Merck through 2031, including accelerated depreciation, exit premiums and fees, technology transfer costs, stability and qualification batch costs, one-time resourcing costs, regulatory and filing costs, capital investment, and inventory stock bridges . The company expects to continue to generate positive cash flow from operations .

Planned capital allocation includes funding operations, working capital needs, capital expenditures, repayment of borrowings, strategic business development transactions, and dividend payments . As of December 31, 2025, total potential payments for contractual milestones are $2.2 billion , with $75 million due within the next twelve months. Purchase obligations total $1.1 billion through 2033, with $298 million due within the next twelve months. Long-term debt obligations total $8.7 billion through 2034, with $10 million due within the next twelve months, and approximately $3.6 billion of notes scheduled to mature in 2028. Lease obligations total $176 million through 2041, with $47 million due within the next twelve months. The Board declared a quarterly dividend of $0.02 per share payable on March 12, 2026 .

Management explicitly flagged several structural headwinds and execution risks. The company expects continued negative impact on its general medicines product portfolio from Volume-Based Procurement (VBP) in China for the next several quarters . The potential reinitiation and expansion of the Universal Reimbursement Payment Standard (URPS) program in China could also adversely affect business and results of operations . Additionally, the company expects continued focus by the U.S. government and states on regulating drug pricing and access to medicine, which could impair its ability to compete and have a material adverse impact on its business, financial condition, and results of operations .

Management Sentiments & Priorities

Management's message to shareholders conveys a clear strategic pivot towards deleveraging the business and optimizing its operational model, while maintaining a commitment to its core mission of women's health. The overall tone indicates a proactive approach to financial discipline and efficiency in response to evolving market conditions and internal challenges. Management explicitly stated its goal of accelerating an improvement in net leverage by reducing the dividend payout ratio, pursuing product divestiture transactions, and decreasing the cost structure . This is supported by the 90% reduction in the regular quarterly dividend in 2025 and the divestiture of the Jada System in January 2026 for up to $465 million , with proceeds intended for debt repayment. The three strategic priorities emphasized for the period ahead are: first, deleveraging the business and improving net leverage; second, optimizing the operating model for efficiency and cost savings, including through restructuring initiatives ; and third, continuing to focus on the women's health portfolio and biosimilars for future growth, as evidenced by the FDA approval of Nexplanon's five-year duration of use in January 2026 and the launch of new biosimilars.

Risk Factors

Organon faces material risks across several domains. Macroeconomic risks include adverse developments in the global economy, such as volatility in capital markets, recession, inflation, or deflation, which could negatively impact the ability to grow the business, replace maturing liabilities, or access capital markets . Changes in tax laws, such as the One Big Beautiful Bill Act (OBBBA) enacted in July 2025, are expected to negatively impact the effective tax rate and results of operations . The company is exposed to market risk from fluctuations in currency exchange rates and interest rates, which could adversely affect earnings, cash flows, and equity . Competitive risks are intense, with products facing competition from other research-based pharmaceutical companies, smaller research companies, and generic drug manufacturers, potentially leading to lower prices or reduced market share . Regulatory and geopolitical risks are significant, particularly in the United States, EU, UK, China, and Japan, where governments are increasingly aggressive in containing healthcare costs through pricing and reimbursement controls, formularies, and programs like China's Volume-Based Procurement (VBP) which has reduced prices for affected products by over 50% . The Inflation Reduction Act of 2022 (IRA) and other U.S. presidential administration executive orders aim to lower drug prices, potentially leading to further pricing pressures . Operational risks include the reliance on single contract manufacturers and/or sole sources of supply for many products, which could lead to increased costs, product shortages, or lost sales if disruptions occur . The company also identified material weaknesses in its internal control over financial reporting related to sales practices for Nexplanon to U.S. wholesalers, which could impact the accuracy and timeliness of future financial reports and potentially lead to litigation or regulatory actions . The company recognized a $301 million goodwill impairment charge in 2025, reflecting continued pressure on the U.S. reporting unit due to lower-than-expected financial performance from patent-protected products, revised projections, adverse geopolitical conditions, and macroeconomic uncertainty .

References

  1. [1] Item 1, Business — Overview
  2. [2] Item 1, Business — Overview
  3. [3] Item 1, Business — Overview
  4. [4] Item 1, Business — Overview
  5. [5] Item 1, Business — Overview
  6. [6] Item 1, Business — Products
  7. [7] Item 1, Business — Products
  8. [8] Item 1, Business — Women’s Health Portfolio
  9. [9] Item 1, Business — Women’s Health Portfolio
  10. [10] Item 1, Business — Women’s Health Portfolio
  11. [11] Item 1, Business — Products
  12. [12] Item 1, Business — Products
  13. [13] Item 1, Business — General Medicines: Biosimilars
  14. [14] Item 1, Business — Products
  15. [15] Item 1, Business — Products
  16. [16] Item 1, Business — Established Brands
  17. [17] Item 1, Business — Established Brands
  18. [18] Item 1, Business — Established Brands
  19. [19] Item 7, MD&A — Operating Results — Sales Overview
  20. [20] Item 7, MD&A — Operating Results — Sales Overview
  21. [21] Item 7, MD&A — Operating Results — Gross Profit, Expenses and Other
  22. [22] Item 7, MD&A — Operating Results — Gross Profit, Expenses and Other
  23. [23] Item 8, Consolidated Statements of Income
  24. [24] Item 8, Consolidated Statements of Income
  25. [25] Item 8, Consolidated Balance Sheets
  26. [26] Item 8, Consolidated Balance Sheets
  27. [27] Item 7, MD&A — Operating Results — Sales Overview
  28. [28] Item 7, MD&A — Operating Results — Sales Overview
  29. [29] Item 7, MD&A — Operating Results — Gross Profit, Expenses and Other
  30. [30] Item 7, MD&A — Operating Results — Gross Profit, Expenses and Other
  31. [31] Item 7, MD&A — Operating Results — Gross Profit, Expenses and Other
  32. [32] Item 7, MD&A — Operating Results — Gross Profit, Expenses and Other
  33. [33] Item 7, MD&A — Operating Results — Gross Profit, Expenses and Other
  34. [34] Item 7, MD&A — Operating Results — Research and Development
  35. [35] Item 7, MD&A — Recent Developments — Business Development — Biogen Inc. (“Biogen”)
  36. [36] Item 3, Acquisitions and Licensing Arrangements — 2025 Transactions — Shanghai Henlius Biotech, Inc. (“Henlius”)
  37. [37] Item 1, Business — General Medicines: Biosimilars
  38. [38] Item 3, Acquisitions and Licensing Arrangements — 2025 Transactions — Oss Biotech Site
  39. [39] Item 7, MD&A — Recent Developments — Business Development — Laborie Medical Technologies Corporation (“Laborie”)
  40. [40] Item 1A, Risk Factors — Risks Related to Our Business — We may not be able to successfully execute our plan to deleverage our business or otherwise reduce our debt level, which could adversely affect our operating flexibility, business, financial condition, results of operations, or cash flows.
  41. [41] Item 1, Business — Recent Developments
  42. [42] Item 1, Business — Recent Developments
  43. [43] Item 1, Business — Recent Developments
  44. [44] Item 1, Business — Women’s Health Portfolio — Contraception
  45. [45] Item 1, Business — Intellectual Property
  46. [46] Item 1, Business — Women’s Health Portfolio — Contraception
  47. [47] Item 1, Business — Intellectual Property
  48. [48] Item 1, Business — General Medicines: Biosimilars
  49. [49] Item 1, Business — General Medicines: Biosimilars
  50. [50] Item 1, Business — General Medicines: Biosimilars
  51. [51] Item 7, MD&A — Recent Developments — Business Development — Biogen Inc. (“Biogen”)
  52. [52] Item 7, MD&A — Recent Developments — Business Development — Biogen Inc. (“Biogen”)
  53. [53] Item 7, MD&A — Liquidity and Capital Resources
  54. [54] Item 7, MD&A — Liquidity and Capital Resources
  55. [55] Item 7, MD&A — Liquidity and Capital Resources
  56. [56] Item 7, MD&A — Contractual Obligations
  57. [57] Item 7, MD&A — Contractual Obligations
  58. [58] Item 7, MD&A — Contractual Obligations
  59. [59] Item 7, MD&A — Contractual Obligations
  60. [60] Item 7, MD&A — Contractual Obligations
  61. [61] Item 7, MD&A — Contractual Obligations
  62. [62] Item 7, MD&A — Contractual Obligations
  63. [63] Item 7, MD&A — Contractual Obligations
  64. [64] Item 7, MD&A — Contractual Obligations
  65. [65] Item 5, Market for Registrant’s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities — Dividends
  66. [66] Item 7, MD&A — Key Trends Affecting Our Results of Operations — Generic Competition
  67. [67] Item 1, Business — Competition — China
  68. [68] Item 1, Business — Competition — United States
  69. [69] Item 1A, Risk Factors — Adverse developments in the global economy or in one or more of our local markets could impact our ability to grow our business.
  70. [70] Item 1A, Risk Factors — Changes in tax laws or other tax guidance could adversely affect our effective tax rates, financial condition or results of operations.
  71. [71] Item 1A, Risk Factors — We are exposed to market risk from fluctuations in currency exchange rates and interest rates.
  72. [72] Item 1A, Risk Factors — We face intense competition from competitors’ products.
  73. [73] Item 1, Business — Competition — China
  74. [74] Item 1, Business — Competition — United States
  75. [75] Item 1A, Risk Factors — We may experience difficulties or delays or incur unforeseen difficulties, delays and expenses in connection with the manufacturing of certain of our products.
  76. [76] Item 1A, Risk Factors — We identified material weaknesses in our internal control over financial reporting, which could impact our ability to report our results of operations and financial condition accurately and in a timely manner.
  77. [77] Item 1A, Risk Factors — An impairment of our Goodwill could materially impact our financial condition and results of operations.
  78. [78] Item 1, Business — Recent Developments
  79. [79] Item 1, Business — Recent Developments
  80. [80] Item 1, Business — Recent Developments
  81. [81] Item 1, Business — Recent Developments
  82. [82] Item 1, Business — Women’s Health Portfolio — Contraception

Analysis on 5/22/2026